X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALE.F02 (Lixudebart Rituximab GlucoCorticoid) is a claudin 1 inhibitor antibody drug candidate, which is currently being evaluated for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.
Lead Product(s): Lixudebart,Rituximab,GlucoCorticoid
Therapeutic Area: Immunology Product Name: ALE.F02
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
ALE.C04, a first-in-class monoclonal antibody developed to specifically target exposed CLDN1 on cancer cells, is being developed in Phase 1/2 as a single agent and in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
Lead Product(s): ALE.C04,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALE.C04
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
ALE.C04 is a first-in-class monoclonal antibody developed to specifically target exposed CLDN1 on cancer cells. This investigational antibody is designed to treat patients with recurrent or metastatic, CLDN1-positive HNSCC.
Lead Product(s): ALE.C04
Therapeutic Area: Oncology Product Name: ALE.C04
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
ALE.F02 is a mAb which works by targeting Claudin-1 (CLDN1), designed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs and is currently under development for kidney, lung, and liver fibrosis.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing April 13, 2023
Details:
ALE.F02 is a highly selective anti-CLDN1 mAb that recognizes pathological overexpressed and conformation-dependent CLDN1 epitopes on transformed epithelial cells and is being investigated for the treatment of fibrotic disease in the kidney, lung and liver.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Alentis dosed first cohort of healthy participants in Phase 1 clinical trial of ALE.F02, a monoclonal antibody highly selective for Claudin-1 for treatment of liver and kidney fibrosis. ALE.F02 has demonstrated compelling safety and efficacy in preclinical patient-derived models of liver and kidney fibrosis.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
Alentis’ lead molecules ALE.F02 and ALE.C04 are highly selective anti-Claudin-1 mAb that recognize pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease and cancer.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morningside Venture
Deal Size: $67.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
